Ex-Acrobot CEO to head up Reapplix
This article was originally published in Clinica
Privately-held Danish wound care specialist Reapplix has appointed Graeme Brookes CEO. Mr Brookes previously led robotic technology specialist Acrobot, before it was acquired by UK orthopedics firm Stanmore Implants in 2010. After the takeover, he was Stanmore’s global vice-president for product development and product marketing. Mr Brookes has also held senior roles at Johnson & Johnson and Advanced Medical Solutions. He replaces Reapplix founder Niels Erik Holm, who will become chief operating officer. Birkerød-based Reapplix’s lead product is LeucoPatch, a proprietary biological “patch” that is produced at point of use from a patient’s own blood, and is designed for the management of hard to heal wounds. The patch, which is already CE marked for sale in Europe, is currently being evaluated for the treatment of diabetic foot ulcers in a randomized controlled clinical study. Reapplix is backed by three leading Danish investors, Novo Seeds, SEED Capital and Vækstfonden (The Danish Growth Fund).